Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...
Sight Sciences, Inc.'s share price has fallen by -13.3% in the past 3 weeks, despite reporting a narrower-than-expected net loss in Q1 and sticking to its 2023 guidance. Sight Sciences' key Q1 2023 ...
BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares. The company delivered a Q3 revenue miss and large guide-down, ...
Canaccord raised the firm’s price target on Exact Sciences (EXAS) to $95 from $75 and keeps a Buy rating on the shares. The firm said they are bullish heading into earnings and 2025 as recent weakness ...
UBS raised the firm’s price target on Sight Sciences (SGHT) to $12 from $7 and keeps a Buy rating on the shares. Medicare Administrative Contractors Novitas and First Coast Service Option established ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback